• 23. Februar 2025

Merck to Present Data on MAVENCLAD(TM) (Cladribine Tablets) and Rebif® (interferon beta-1a) in Patients with Relapsing MS at EAN Congress 2017

ByMerck KGaA

Juni 25, 2017